Allergan calls a cease-fire after thousands of job cuts at its HQ

Allergan ($AGN), still working through its $66 billion merger with Actavis, is through shedding jobs at its California headquarters, CEO Brent Saunders said, moving on from laying off more than 1,000 workers over the past year. The company's Irvine, CA, home base has been repeatedly downsized as Allergan worked to fend off unwanted attention from Valeant Pharmaceuticals ($VRX) and again after Actavis won the bidding war. Now, however, "the cuts are done," Saunders told the LA Times. "There is no second shoe to drop. The people who are there are there." More from FiercePharma

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.